As discussed above, existing M1R antagonists are currently under clinical investigation for repurposing as therapy for peripheral neuropathy, although there is considerable room for advancing novel second generation agents that offer more precise targeting. This evidence concerns the gene CHRM1 and peripheral neuropathy.